AKRO Stock Price, Akero Therapeutics Inc Quote, Chart

Market Summary

USD20.26-0.74

Market Closed

-3.52%

AKRO Alerts

1 major insider sales recently.

AKRO Stock Price

View Fullscreen

AKRO RSI Chart

AKRO Valuation

Market Cap

1.1B

Price/Earnings (Trailing)

-7.52

Price/Sales (Trailing)

47.11

Price/Free Cashflow

-7.85

AKRO Price/Sales (Trailing)

AKRO Profitability

Return on Equity

-28.35%

Return on Assets

-26.15%

Free Cashflow Yield

-12.74%

AKRO Fundamentals

AKRO Revenue

Revenue (TTM)

24.2M

AKRO Earnings

Earnings (TTM)

-151.8M

Earnings Growth (Yr)

-139.33%

Earnings Growth (Qtr)

-39.15%

Breaking Down AKRO Revenue

Last 7 days

-6.2%

Last 30 days

-16.2%

Last 90 days

-8.2%

Trailing 12 Months

-54.8%

How does AKRO drawdown profile look like?

AKRO Financial Health

Current Ratio

29.27

AKRO Investor Care

Shares Dilution (1Y)

19.86%

Diluted EPS (TTM)

-2.89

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	8.9M	14.0M	19.1M	24.2M
2022	0	0	0	3.9M
2021	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Akero Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 01, 2024	young jonathan	sold	-111,903	24.3267	-4,600	chief operating officer
Apr 01, 2024	young jonathan	sold	-10,010	25.025	-400	chief operating officer
Mar 13, 2024	white william richard	sold	-20,510	28.33	-724	chief financial officer
Mar 13, 2024	cheng andrew	sold	-55,781	28.33	-1,969	president and ceo
Mar 13, 2024	yale catriona	sold	-20,482	28.33	-723	chief development officer
Mar 13, 2024	young jonathan	sold	-18,442	28.33	-651	chief operating officer
Mar 13, 2024	rolph timothy	sold	-17,536	28.33	-619	chief scientific officer
Mar 04, 2024	cheng andrew	sold	-2,465,060	32.8675	-75,000	president and ceo
Mar 04, 2024	cheng andrew	acquired	1,288,060	17.1742	75,000	president and ceo
Mar 04, 2024	yale catriona	sold	-732,727	35.49	-20,646	chief development officer

Which funds bought or sold AKRO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	Global Retirement Partners, LLC	added	54.53	63,239	145,169	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-71.64	-119,000	52,000	-%
Apr 23, 2024	Gradient Investments LLC	sold off	-100	-23.00	-	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	-735,074	630,333	-%
Apr 19, 2024	Cutler Group LLC / CA	added	100	8,000	15,000	-%
Apr 19, 2024	BOURGEON CAPITAL MANAGEMENT LLC	new	-	382,689	382,689	0.07%
Apr 19, 2024	ZRC WEALTH MANAGEMENT, LLC	added	500	1,010	1,516	-%
Apr 18, 2024	QUATTRO FINANCIAL ADVISORS LLC	added	43,378	19,100	252,600	0.07%
Apr 10, 2024	Banque Cantonale Vaudoise	unchanged	-	2,000	25,000	-%
Apr 10, 2024	SOA Wealth Advisors, LLC.	unchanged	-	388	5,128	-%

Are Funds Buying or Selling AKRO?

Are funds buying AKRO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AKRO

No. of Funds

AKRO Alerts

1 major insider sales recently.

Unveiling Akero Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 15, 2024	general atlantic, l.p.	7.7%	5,233,989	SC 13G
Feb 14, 2024	price t rowe associates inc /md/	6.6%	3,681,209	SC 13G
Feb 14, 2024	pfizer inc	4.53%	2,525,252	SC 13G/A
Feb 14, 2024	rtw investments, lp	6.4%	3,592,759	SC 13G
Feb 14, 2024	redmile group, llc	2.0%	1,109,476	SC 13G/A
Feb 14, 2024	baker bros. advisors lp	4.3%	2,368,378	SC 13G/A
Feb 13, 2024	avidity partners management lp	0.4%	235,000	SC 13G/A
Feb 13, 2024	janus henderson group plc	7.7%	4,306,401	SC 13G/A
Feb 13, 2024	alkeon capital management llc	6.8%	3,764,220	SC 13G/A
Feb 13, 2024	vanguard group inc	5.54%	3,085,048	SC 13G

Recent SEC filings of Akero Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 16, 2024	PRE 14A	PRE 14A
Apr 03, 2024	4	Insider Trading
Apr 01, 2024	144	Notice of Insider Sale Intent
Mar 18, 2024	8-K	Current Report
Mar 15, 2024	4	Insider Trading
Mar 15, 2024	SC 13G	Major Ownership Report
Mar 15, 2024	4	Insider Trading
Mar 15, 2024	4	Insider Trading
Mar 15, 2024	4	Insider Trading
Mar 15, 2024	4	Insider Trading

Peers (Alternatives to Akero Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	-1.39%	-19.31%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-5.44%	-28.86%	-41.14	9.91	76.23%	61.08%
BMRN	17.2B	2.4B	5.41%	-4.57%	102.64	7.11	15.42%	18.43%
INCY	11.6B	3.7B	-9.99%	-29.65%	19.44	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-10.10%	-42.90%	-11.39	15.18	425.83%	18.94%
BBIO	4.4B	-	-14.83%	70.74%	-6.74	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-7.99%	-0.08%	-14.09	12.46	440.80%	-27.84%
ARWR	2.9B	240.7M	-16.49%	-30.64%	-9.72	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-7.01%	-17.50%	-44.6	3.76	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.67%	-6.03%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-13.72%	-45.61%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	-0.25%	294.45%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-18.06%	3.25%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	70.91%	57.98%	-0.24	2.14	-13.45%	66.37%

Akero Therapeutics Inc News

Latest updates

Akero Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)						(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2021Q4
Operating Expenses	32.7%	61,873	46,615	35,629	28,753	25,420	32,439
S&GA Expenses	6.3%	8,481	7,981	7,644	6,966	7,100	4,728
R&D Expenses	38.2%	53,392	38,634	27,985	21,787	18,320	27,711
Interest Expenses	1.0%	897	888	857	457	-	-
Net Income	-39.2%	-55,186	-39,659	-31,083	-25,831	-23,059	-32,424
Net Income Margin	-0.2%	-6.27*	-6.26*	-	-	-	-86.38*
Free Cashflow	2.2%	-48,627	-49,719	-22,389	-24,632	-25,508	-26,695

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																				(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2018Q4
Assets	-8.7%	580	635	664	349	357	379	186	170	196	224	238	258	273	300	114	127	138	150	163	77.00
Current Assets	-2.8%	560	576	643	347	355	378	184	168	194	222	236	256	271	298	113	126	138	150	163	77.00
Cash Equivalents	-13.1%	234	270	444	258	250	374	178	151	151	165	158	188	187	193	63.00	47.00	65.00	148	163	76.00
Net PPE	-10.0%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	-	-	-
Liabilities	-13.9%	45.00	52.00	47.00	42.00	30.00	36.00	37.00	23.00	26.00	25.00	18.00	12.00	15.00	14.00	10.00	8.00	9.00	7.00	5.00	2.00
Current Liabilities	-32.8%	19.00	28.00	22.00	17.00	19.00	25.00	27.00	22.00	25.00	24.00	16.00	10.00	13.00	12.00	10.00	8.00	9.00	7.00	5.00	2.00
Shareholder's Equity	-8.2%	535	583	616	306	327	344	148	147	169	199	220	246	259	286	104	118	129	143	158	-
Retained Earnings	-10.6%	-574	-518	-479	-448	-422	-399	-363	-336	-310	-277	-253	-224	-209	-179	-158	-142	-130	-114	-99.15	-86.56
Additional Paid-In Capital	0.6%	1,109	1,103	1,096	754	749	743	512	483	479	477	474	471	468	466	262	260	259	258	258	37.00
Shares Outstanding	0.1%	56.00	56.00	56.00	47.00	47.00	39.00	35.00	35.00	35.00	35.00	35.00	35.00	-	-	-	-	-	-	-	-
Float	-	-	-	2,518	-	-	-	340,435	-	-	-	768	-	-	-	478	-	-	-	196	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	2.2%	-48,627	-49,719	-22,389	-24,632	-25,508	-24,624	-19,509	-22,876	-26,695	-14,606	-20,034	-18,346	-23,395	-13,508	-22,584	-11,317	-11,649	-13,212	-5,322	-5,444	-
Share Based Compensation	6.6%	6,116	5,739	4,798	4,844	4,040	11,731	4,161	3,311	2,642	2,612	2,436	2,364	1,916	1,546	1,323	1,237	670	483	402	215	-
Cashflow From Investing	110.2%	12,786	-125,697	-128,302	17,590	-101,445	3,000	11,870	22,750	12,000	21,934	-10,654	19,000	17,899	-59,844	38,465	-6,281	-	-	-	-	-
Cashflow From Financing	-37.7%	502	806	336,855	15,153	2,723	217,900	34,877	132	243	69.00	266	24.00	59.00	202,784	100	164	115	-1,607	98,200	-720	-

AKRO Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Operating expenses:
Research and development	$ 141,798	$ 85,284	$ 81,759
General and administrative	31,072	29,872	19,127
Total operating expenses	172,870	115,156	100,886
Loss from operations	(172,870)	(115,156)	(100,886)
Interest expense	(3,099)	(739)
Interest and other income, net	24,210	3,862	109
Net loss	(151,759)	(112,033)	(100,777)
Net unrealized gain (loss) on marketable securities	233	64	(24)
Comprehensive loss	$ (151,526)	$ (111,969)	$ (100,801)
Net loss per share, basic	$ (2.89)	$ (2.87)	$ (2.89)
Net loss per share, diluted	$ (2.89)	$ (2.87)	$ (2.89)
Weighted-average number of shares used in computing net loss per common share, basic	52,568,159	38,984,772	34,827,385
Weighted-average number of shares used in computing net loss per common share, diluted	52,568,159	38,984,772	34,827,385

AKRO Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 234,207	$ 249,773
Short-term marketable securities	315,803	101,676
Prepaid expenses and other current assets	9,952	3,724
Total current assets	559,962	355,173
Long-term marketable securities	19,283
Property and equipment, net	18	47
Right of use asset	1,008	1,242
Other assets, noncurrent		108
Total assets	580,271	356,570
Current liabilities:
Accounts payable	7,038	7,968
Accrued expenses and other current liabilities	12,090	11,115
Total current liabilities	19,128	19,083
Loan payable, noncurrent	24,964	9,541
Warrant liability	54	305
Operating lease liability, noncurrent	819	1,079
Total liabilities	44,965	30,008
Commitments and contingencies (Note 12)
Stockholders' equity:
Common stock, $0.0001 par value, 150,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 55,754,445 and 46,865,206 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively	6	5
Additional paid-in capital	1,109,126	748,857
Accumulated other comprehensive income	270	37
Accumulated deficit	(574,096)	(422,337)
Total stockholders' equity	535,306	326,562
Total liabilities and stockholders' equity	$ 580,271	$ 356,570

About Akero Therapeutics Inc

Akero Therapeutics, Inc., a clinical-stage company, engages in the development of transformational treatments for patients with serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company is also conducting a Phase 2b clinical trial to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

CEO	Dr. Andrew Cheng M.D., Ph.D.
WEBSITE	akerotx.com
INDUSTRY	Biotechnology
EMPLOYEES	44

Akero Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Akero Therapeutics Inc? What does AKRO stand for in stocks?

AKRO is the stock ticker symbol of Akero Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Akero Therapeutics Inc (AKRO)?

As of Wed Apr 24 2024, market cap of Akero Therapeutics Inc is 1.14 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AKRO stock?

You can check AKRO's fair value in chart for subscribers.

What is the fair value of AKRO stock?

You can check AKRO's fair value in chart for subscribers. The fair value of Akero Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Akero Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AKRO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Akero Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether AKRO is over valued or under valued. Whether Akero Therapeutics Inc is cheap or expensive depends on the assumptions which impact Akero Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AKRO.

What is Akero Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 24 2024, AKRO's PE ratio (Price to Earnings) is -7.52 and Price to Sales (PS) ratio is 47.11. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AKRO PE ratio will change depending on the future growth rate expectations of investors.